Data demonstrated multiple clinical benefits beyond linear growth— NDA supported by data from three randomized, double-blind, ...

NORCROSS, Ga., March 31, 2025 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today reported financial results and ...

Apnimed, Inc., a pharmaceutical company building the industry-leading portfolio of first-in-class oral drug candidates that address the root causes of obstructive sleep apnea (OSA) and other ...

Analyses from Randomized Controlled Trials Further Support the Target Engagement and Safety Profile of Ampreloxetine in Neurodegenerative Disease< ...

Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today reported financial results and ...

Pistachio ice cream is a top pick for many people, but not all brands are ranked the same when it comes to this flavor. We ...

AstraZenca is testing a once-daily PCSK9 inhibitor, currently known as AZD0780. After 12 weeks of use alongside standard ...

Among patients with uncontrolled hypertension, the investigational drug lorundrostat brought a significant reduction in blood pressure at 12 weeks compared with placebo, according to a study presented ...

Twenty-four-hour average ambulatory blood pressure, the trial's primary endpoint, dropped by 7.9 mm Hg and 6.5 mm Hg more than placebo in the two study groups that received the drug (with one ...

For decades, the placebo effect — the phenomenon where a patient’s condition improves after receiving an inert treatment, often a sugar pill, because they believe it to be real medication ...

BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading biotechnology company developing cutting-edge cell therapies for neurodegenerative diseases, today announced the submission of an ...